Track topics on Twitter Track topics that are important to you
Pfizer has announced top-line results from a second Phase 3 study evaluating the efficacy and safety of its oral JAK1 inhibitor, abrocitinib, in patients aged 12 or over with moderate to severe atopic dermatitis.
The study, called JADE MONO-2, used 391 subjects and was designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over the course of 12 weeks.
Original Article: Pfizer reports positive phase 3 data in atopic dermatitisNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...